Strategic clinical development, delivered with care.

We translate scientific rationale and commercial intent into a coherent clinical development plan. From target product profile to phased decision points, we deliver a roadmap your team — and your board — can rely on.

• — Target product profile (TPP)
• — Integrated development plan (IDP)
• — Indication sequencing & prioritization
• — Go / no-go decision frameworks

We map the regulatory journey across EMA, FDA and other authorities, and prepare you for the conversations that matter — from scientific advice and pre-IND to end-of-Phase-2 and beyond.

• — Regulatory strategy across EMA / FDA
• — Scientific advice & briefing books
• — Orphan, PRIME, breakthrough designations
• — Agency interaction preparation

Sound design is the cheapest risk mitigation in clinical research. We craft study concepts and protocol skeletons that balance scientific rigor, regulatory expectation and operational feasibility.

• — Phase 1–3 study concepts
• — Endpoint & population selection
• — Adaptive & seamless designs
• — Protocol authoring support

An external strategic perspective at the right moment — for due diligence, in-licensing, partnering decisions or board reviews. Concise, candid, and rooted in clinical and regulatory experience.

• — Clinical & regulatory due diligence
• — Asset & platform assessments
• — KOL and advisory board planning
• — Lifecycle and label expansion strategy

Hands-on operational delivery and oversight across the trial lifecycle — from start-up and site activation to monitoring, vendor governance and database lock. We bring GCP-grade rigor to studies of every size, with particular depth in oncology trials.

• — Trial start-up & country/site selection
• — Site activation, monitoring & oversight
• — CRO & vendor selection and governance
• — Risk-based quality management (ICH E6 R3)
• — Investigator meetings & site engagement
• — Study close-out and database lock readiness

Senior medical oversight for ongoing studies and programs — protocol interpretation, eligibility and safety review, medical monitoring, and scientific engagement with investigators, KOLs and ethics committees.

• — Medical monitoring & safety review
• — Eligibility and protocol deviation adjudication
• — Investigator and KOL scientific engagement
• — Medical input to DSMB / IDMC interactions
• — Scientific & medical writing oversight

We help you plan and generate evidence that complements clinical trial data — from registries and observational studies to secondary data analyses — to support regulatory, HTA and access decisions across the product lifecycle.

• — RWE strategy & evidence planning
• — Observational & registry study design
• — Secondary data source assessment
• — Regulatory, HTA & payer-grade RWE